Search

Your search keyword '"Abraham, William T."' showing total 2,702 results
Start Over Author "Abraham, William T."
2,702 results on '"Abraham, William T."'

158. Aptamer Proteomics for Biomarker Discovery in Heart Failure With Reduced Ejection Fraction

Author

Zhang, Luqing, primary, Cunningham, Jonathan W., additional, Claggett, Brian L., additional, Jacob, Jaison, additional, Mendelson, Michael M., additional, Serrano-Fernandez, Pablo, additional, Kaiser, Sergio, additional, Yates, Denise P., additional, Healey, Margaret, additional, Chen, Chien-Wei, additional, Turner, Gordon M., additional, Patel-Murray, Natasha L., additional, Zhao, Faye, additional, Beste, Michael T., additional, Laramie, Jason M., additional, Abraham, William T., additional, Jhund, Pardeep S., additional, Kober, Lars, additional, Packer, Milton, additional, Rouleau, Jean, additional, Zile, Michael R., additional, Prescott, Margaret F., additional, Lefkowitz, Martin, additional, McMurray, John J.V., additional, Solomon, Scott D., additional, and Chutkow, William, additional

Published
2022
Full Text
View/download PDF

159. Prediction of Death or HF Hospitalization in Patients With Severe FMR

Author

Shah, Neeraj, primary, Madhavan, Mahesh V., additional, Gray, William A., additional, Brener, Sorin J., additional, Ahmad, Yousif, additional, Lindenfeld, JoAnn, additional, Abraham, William T., additional, Grayburn, Paul A., additional, Kar, Saibal, additional, Lim, D. Scott, additional, Mishell, Jacob M., additional, Whisenant, Brian K., additional, Zhang, Zixuan, additional, Redfors, Bjorn, additional, Mack, Michael J., additional, and Stone, Gregg W., additional

Published
2022
Full Text
View/download PDF

160. Guideline-directed medical treatment in patients undergoing transcatheter edge-to-edge repair for secondary mitral regurgitation

Author

Higuchi, Satoshi, Orban, Mathias, Adamo, Marianna, Giannini, Cristina, Melica, Bruno, Karam, Nicole, Praz, Fabien, Kalbacher, Daniel, Koell, Benedikt, Stolz, Lukas, Braun, Daniel, Näbauer, Michael, Wild, Mirjam, Doldi, Philipp, Neuss, Michael, Butter, Christian, Kassar, Mohammad, Ruf, Tobias, Petrescu, Aniela, Ludwig, Sebastian, Pfister, Roman, Iliadis, Christos, Unterhuber, Matthias, Sampaio, Francisco, Ferreira, Diogo, Thiele, Holger, Baldus, Stephan, von Bardeleben, Ralph Stephan, Massberg, Steffen, Windecker, Stephan, Lurz, Philipp, Petronio, Anna Sonia, Lindenfeld, JoAnn, Abraham, William T, Metra, Marco, and Hausleiter, Jörg

Subjects
Secondary mitral regurgitation, Guideline-directed medical therapy, 610 Medicine & health, Comorbidities, Heart failure with reduced ejection fraction, Residual mitral regurgitation, Transcatheter edge-to-edge-repair, Cardiology and Cardiovascular Medicine
Abstract

INTRODUCTION Guideline-directed medical therapy (GDMT), based on the combination of beta blockers (BB), renin-angiotensin system inhibitors (RAS-I), and mineralocorticoid-receptor antagonists (MRA), is known to have a major impact on the outcome of the patients with heart failure with reduced ejection fraction (HFrEF). Although GDMT is recommended prior to M-TEER, not all patients tolerate it. We studied the association of GDMT prescription with survival in HFrEF patients undergoing mitral valve transcatheter edge-to-edge repair (M-TEER) for secondary mitral regurgitation (SMR). METHODS AND RESULTS EuroSMR, a European multicenter registry, included SMR patients with left ventricular ejection fraction of less than fifty percent. The outcome was 2-year all-cause mortality. Of 1344 patients, BB, RAS-I, and MRA were prescribed in 1169 (87%), 1012 (75%), and 765 (57%) patients at the time of M-TEER, respectively. Triple GDMT prescription was associated with a lower 2-year all-cause mortality compared to non-triple GDMT (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.60-0.91). The association persisted in patients with glomerular filtration rate of

Published
2022

164. Functional Mitral Regurgitation Staging and its Relationship to Outcomes in the COAPT Trial

Author

Cavalcante, João L., primary, Asch, Federico M., additional, Garcia, Santiago, additional, Weissman, Neil J., additional, Sorajja, Paul, additional, Zhou, Zhipeng, additional, Hahn, Rebecca T., additional, Lindenfeld, JoAnn, additional, Abraham, William T., additional, Redfors, Björn, additional, Mack, Michael J., additional, and Stone, Gregg W., additional

Published
2022
Full Text
View/download PDF

165. Predicting stroke in heart failure and reduced ejection fraction without atrial fibrillation

Author

Kondo, Toru, primary, Abdul-Rahim, Azmil H, additional, Talebi, Atefeh, additional, Abraham, William T, additional, Desai, Akshay S, additional, Dickstein, Kenneth, additional, Inzucchi, Silvio E, additional, Køber, Lars, additional, Kosiborod, Mikhail N, additional, Martinez, Felipe A, additional, Packer, Milton, additional, Petrie, Mark, additional, Ponikowski, Piotr, additional, Rouleau, Jean L, additional, Sabatine, Marc S, additional, Swedberg, Karl, additional, Zile, Michael R, additional, Solomon, Scott D, additional, Jhund, Pardeep S, additional, and McMurray, John J V, additional

Published
2022
Full Text
View/download PDF

166. Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta‐analysis of randomized controlled trials

Author

Coats, Andrew J.S., primary, Abraham, William T., additional, Zile, Michael R., additional, Lindenfeld, Joann A., additional, Weaver, Fred A., additional, Fudim, Marat, additional, Bauersachs, Johann, additional, Duval, Sue, additional, Galle, Elizabeth, additional, and Zannad, Faiez, additional

Published
2022
Full Text
View/download PDF

170. Abstract 18347: Prognostic Significance of Activation Delay by Cross Correlation Analysis Using Tissue Doppler Imaging in Patients With Heart Failure and Narrow QRS Duration; an Echocardiography Guided Cardiac Resynchronization Therapy (Echo-CRT) Trial Substudy of Patients Not Randomized to CRT

Author

Tayal, Bhupendar, Gorcsan 3rd, John, Bax, Jeroen, Risum, Niels, Olsen, Niels Thue, Singh, Jagmeet P, Abraham, William T, Borer, Jeffrey S, Dickstein, Kenneth, Gras, Daniel, Krum, Henry, Brugada, Josep, Robertson, Michele, Ford, Ian, Holzmeister, Johannes, Ruschitzka, Frank, and Sogaard, Peter

Published
2017

171. Abstract 16367: Treatment With Insulin is Associated With Worse Outcome in Patients With Chronic Heart Failure and Diabetes

Author

Cosmi, Franco, Shen, Li, Magnoli, Michela, Abraham, William T, Anand, Inder S, Cleland, John G, Cohn, Jay N, Cosmi, Deborah, De Berardis, Giorgia, Dickstein, Kenneth, Franzosi, Maria Grazia, Gullestad, Lars, Jhund, Pardeep S, Kjekshus, John, Køber, Lars, Lepore, Vito, Lucisano, Giuseppe, Maggioni, Aldo P, Masson, Serge, McMurray, John J, Nicolucci, Antonio, Petrarolo, Vito, Robusto, Fabio, Staszewsky, Lidia, Tavazzi, Luigi, Teli, Roberto, Tognoni, Gianni, Wikstrand, John, and Latini, Roberto

Published
2017

172. Contemporary Characteristics and Outcomes in Chagasic Heart Failure Compared With Other Nonischemic and Ischemic Cardiomyopathy

Author

Shen, Li, Ramires, Felix, Martinez, Felipe, Bodanese, Luiz Carlos, Echeverría, Luis Eduardo, Gómez, Efraín A., Abraham, William T., Dickstein, Kenneth, Køber, Lars, Packer, Milton, Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Zile, Michael R., Jhund, Pardeep S., Gimpelewicz, Claudio R., and McMurray, John J.V.

Published
2017
Full Text
View/download PDF

175. Impact of multimorbidity on mortality in heart failure with reduced ejection fraction: which comorbidities matter most? An analysis of PARADIGM‐HF and ATMOSPHERE.

Author

Dewan, Pooja, Ferreira, João Pedro, Butt, Jawad H., Petrie, Mark C., Abraham, William T., Desai, Akshay S., Dickstein, Kenneth, Køber, Lars, Packer, Milton, Rouleau, Jean L., Stewart, Simon, Swedberg, Karl, Zile, Michael R., Solomon, Scott D., Jhund, Pardeep S., and McMurray, John J.V.

Subjects
HEART failure, VENTRICULAR ejection fraction, COMORBIDITY, PROPORTIONAL hazards models, PERIPHERAL vascular diseases, ACE inhibitors
Abstract

Aims: Multimorbidity, the coexistence of two or more chronic conditions, is synonymous with heart failure (HF). How risk related to comorbidities compares at individual and population levels is unknown. The aim of this study is to examine the risk related to comorbidities, alone and in combination, both at individual and population levels. Methods and results: Using two clinical trials in HF – the Prospective comparison of ARNI (Angiotensin Receptor–Neprilysin Inhibitor) with ACEI (Angiotensin‐Converting Enzyme Inhibitor) to Determine Impact on Global Mortality and morbidity in HF trial (PARADIGM‐HF) and the Aliskiren Trial to Minimize Outcomes in Patients with Heart Failure trials (ATMOSPHERE) – we identified the 10 most common comorbidities and examined 45 possible pairs. We calculated population attributable fractions (PAF) for all‐cause death and relative excess risk due to interaction with Cox proportional hazard models. Of 15 066 patients in the study, 14 133 (93.7%) had at least one and 11 867 (78.8%) had at least two of the 10 most prevalent comorbidities. The greatest individual risk among pairs was associated with peripheral artery disease (PAD) in combination with stroke (hazard ratio [HR] 1.73; 95% confidence interval [CI] 1.28–2.33) and anaemia (HR 1.71; 95% CI 1.39–2.11). The combination of chronic kidney disease (CKD) and hypertension had the highest PAF (5.65%; 95% CI 3.66–7.61). Two pairs demonstrated significant synergistic interaction (atrial fibrillation with CKD and coronary artery disease, respectively) and one an antagonistic interaction (anaemia and obesity). Conclusions: In HF, the impact of multimorbidity differed at the individual patient and population level, depending on the prevalence of and the risk related to each comorbidity, and the interaction between individual comorbidities. Patients with coexistent PAD and stroke were at greatest individual risk whereas, from a population perspective, coexistent CKD and hypertension mattered most. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

176. Association between serum albumin and outcomes in heart failure and secondary mitral regurgitation: the COAPT trial.

Author

Feng, Kent Y., Ambrosy, Andrew P., Zhou, Zhipeng, Li, Ditian, Kong, Jeremy, Zaroff, Jonathan G., Mishell, Jacob M., Ku, Ivy A., Scotti, Andrea, Coisne, Augustin, Redfors, Björn, Mack, Michael J., Abraham, William T., Lindenfeld, JoAnn, and Stone, Gregg W.

Subjects
HEART failure, SERUM albumin, MITRAL valve insufficiency, HEART failure patients, ALBUMINS, OVERALL survival
Abstract

Aims: Low serum albumin levels are associated with poor prognosis in numerous chronic disease states but the relationship between albumin and outcomes in patients with heart failure (HF) and secondary mitral regurgitation (SMR) has not been described. Methods and results: The randomized COAPT trial evaluated the safety and effectiveness of transcatheter edge‐to‐edge repair (TEER) with the MitraClipTM plus guideline‐directed medical therapy (GDMT) versus GDMT alone in patients with symptomatic HF and moderate‐to‐severe or severe SMR. Baseline serum albumin levels were measured at enrolment. Among 614 patients enrolled in COAPT, 559 (91.0%) had available baseline serum albumin levels (median 4.0 g/dl, interquartile range 3.7–4.2 g/dl). Patients with albumin <4.0 g/dl compared with ≥4.0 g/dl were older and more likely to have ischaemic cardiomyopathy and a hospitalization within the year prior to enrolment. After multivariable adjustment, patients with albumin <4.0 g/dl had higher 4‐year rates of all‐cause death (63.7% vs. 47.6%; adjusted hazard ratio 1.34, 95% confidence interval 1.02–1.74; p = 0.032), but there were no significant differences in HF hospitalizations (HFH) or all‐cause hospitalizations according to baseline serum albumin level. The relative effectiveness of TEER plus GDMT versus GDMT alone was consistent in patients with low and high albumin levels (pinteraction = 0.19 and 0.35 for death and HFH, respectively). Conclusion: Low baseline serum albumin levels were independently associated with reduced 4‐year survival in patients with HF and severe SMR enrolled in the COAPT trial, but not with HFH. Patients treated with TEER derived similarly robust reductions in both death and HFH regardless of baseline albumin level. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

178. Cost-effectiveness of transcatheter edge-to-edge repair in secondary mitral regurgitation

Author

Cohen, David J., Wang, Kaijun, Magnuson, Elizabeth A., Smith, Robert D., Petrie, Mark C., Buch, Mamta H., Abraham, William T., Lindenfeld, Joann, Mack, Michael J., Stone, Gregg W., and Cleland, John G. F.

Subjects
Heart Failure, Heart Valve Prosthesis Implantation, Cardiac Catheterization, Clinical Trials as Topic, Treatment Outcome, Cost-Benefit Analysis, Humans, Mitral Valve Insufficiency, Stroke Volume, Cardiology and Cardiovascular Medicine, health care economics and organizations, State Medicine, Ventricular Function, Left
Abstract

BackgroundTranscatheter edge-to-edge mitral valve repair (TMVr) improves symptoms and survival for patients with heart failure with reduced left ventricular ejection fraction (HFrEF) and severe secondary mitral regurgitation despite guideline-recommended medical therapy (GRMT). Whether TMVr is cost-effective from a UK National Health Service (NHS) perspective is unknown.MethodsWe used patient-level data from the Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) trial to perform a cost-effectiveness analysis of TMVr +GRMT versus GRMT alone from an NHS perspective. Costs for the TMVr procedure were based on standard English tariffs and device costs. Subsequent costs were estimated based on data acquired during the trial. Health utilities were estimated using the Short-Form 6-Dimension Health Survey.ResultsCosts for the index procedural hospitalisation were £18 781, of which £16 218 were for the TMVr device. Over 2-year follow-up, TMVr reduced subsequent costs compared with GRMT (£10 944 vs £14 932, p=0.006), driven mainly by reductions in heart failure hospitalisations; nonetheless, total 2-year costs remained higher with TMVr (£29 165 vs £14 932, pConclusionsFor patients with HFrEF and severe secondary mitral regurgitation similar to those enrolled in COAPT, TMVr increases life expectancy and quality-adjusted life expectancy compared with GRMT at an ICER that represents good value from an NHS perspective.

Published
2022

179. Hypertensive events after the initiation of contemporary cancer therapies for breast cancer control

Author

Carter, Rebecca R., primary, Chum, Aaron P., additional, Sanchez, Reynaldo, additional, Guha, Avirup, additional, Dey, Amit K., additional, Reinbolt, Raquel, additional, Kim, Lisa, additional, Otchere, Prince, additional, Oppong‐Nkrumah, Oduro, additional, Abraham, William T., additional, Lustberg, Maryam, additional, and Addison, Daniel, additional

Published
2022
Full Text
View/download PDF

180. PO-628-08 RESPONSE TO CRT IS DIFFERENT IN PATIENTS WITH IVCD COMPARED TO RBBB: A PATIENT LEVEL META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Author

Friedman, Daniel J., primary, Al-Khatib, Sana M., additional, Dalgaard, Frederik, additional, Fudim, Marat, additional, Abraham, William T., additional, Cleland, John G.F., additional, Curtis, Anne B., additional, Gold, Michael R., additional, Kutyifa, Valentina, additional, Linde, Cecilia Marianne, additional, Young, James B., additional, Ali-Ahmed, Fatima, additional, Olivas-Martinez, Antonio, additional, Inoue, Lurdes, additional, and Sanders, Gillian D., additional

Published
2022
Full Text
View/download PDF

182. A Novel Approach Using Remote Speech Analysis In Chronic Ambulatory Heart Failure Patients Allows Early Detection Of Clinical Decompensation Leading To Hospitalization Or Unplanned Iv Diuretics Treatment - Updated New Data

Author

Amir, Offer, primary, Ben-Gal, Tuvia, additional, Weinstein, Jean Marc, additional, Murninkas, Daniel, additional, Lakobishvili, Zaza, additional, Shochat, Michael Kleiner, additional, Dragu, Robert, additional, Ouzan, Elisha, additional, Lotan, Chaim, additional, Edelman, Elazer R., additional, Anker, Stefan D., additional, Shallom, Ilan D., additional, Haviv, Ronit, additional, Pinney, Sean P., additional, Burkhoff, Daniel, additional, and Abraham, William T., additional

Published
2022
Full Text
View/download PDF

190. Hypertensive events after the initiation of contemporary cancer therapies for breast cancer control.

Author

Carter, Rebecca R., Chum, Aaron P., Sanchez, Reynaldo, Guha, Avirup, Dey, Amit K., Reinbolt, Raquel, Kim, Lisa, Otchere, Prince, Oppong‐Nkrumah, Oduro, Abraham, William T., Lustberg, Maryam, and Addison, Daniel

Subjects
BREAST cancer, CANCER treatment, HYPERTENSION, HOSPITAL mortality
Abstract

Background: Contemporary therapies improve breast cancer (BC) outcomes. Yet, many of these therapies have been increasingly linked with serious cardiotoxicity, including reports of profound hypertension. Yet, the incidence, predictors, and impacts of these events are largely unknown. Methods: Leveraging two large U.S.‐based registries, the National Inpatient Sample (NIS) and the Food and Drug Administration Adverse Event Reporting System (FAERS) databases, we assessed the incidence, factors, and outcomes of hypertensive events among BC patients from 2007 to 2015. Differences in baseline characteristics, hypertension‐related discharges, and complications were examined over time. Further, we performed a disproportionality analysis using reporting‐odds‐ratios (ROR) to determine the association between individual BC drugs and hypertensive events. Utilizing an ROR cutoff of >1.0, we quantified associations by drug‐class, and individual drugs with the likelihood of excess hypertension. Results: Overall, there were 5,464,401 BC‐admissions, of which 46,989 (0.8%) presented with hypertension. Hypertensive BC patients were older, and saw initially increased in‐hospital mortality, which equilibrated over time. The mean incidence of hypertension‐related admissions was 732 per 100,000 among BC patients, versus 96 per 100,000 among non‐cancer patients (RR 7.71, p < 0.001). Moreover, in FAERS, those with hypertension versus other BC‐treatment side‐effects were more frequently hospitalized (40.1% vs. 36.7%, p < 0.001), and were most commonly associated with chemotherapy (45.9%). Outside of Eribulin (ROR 3.36; 95% CI 1.37–8.22), no specific drug was associated with a higher reporting of hypertension; however, collectively BC drugs were associated with a higher odds of hypertension (ROR 1.66; 95% CI 1.09–2.53). Conclusions: BC therapies are associated with a substantial increase in limiting hypertension. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

194. FUNCTIONAL AND SYMPTOMATIC CLINICAL ENDPOINTS IN HEART FAILURE RESEARCH: INSIGHTS FROM THE HEART FAILURE COLLABORATORY (HFC) - ACADEMIC RESEARCH CONSORTIUM (ARC) SCIENTIFIC EXPERT PANEL

Author

Dimond, Matthew, primary, Fiuzat, Mona, additional, Psotka, Mitchell A., additional, O’Connor, Christopher M., additional, Consortium, Heart Failure Collaboratory-Academic Research, additional, Abraham, William T., additional, Ahmad, Tariq, additional, Anker, Stefan D., additional, Felker, Michael G., additional, Filippatos, Gerasimos, additional, Kitzman, Dalane W., additional, Leifer, Eric, additional, Lewis, Eldrin F., additional, Lindenfeld, JoAnn, additional, Mentz, Robert John, additional, Nkulikiyinka, Richard, additional, Schaber, Dan, additional, Sharma, Abhinav, additional, Solomon, Scott D., additional, Stockbridge, Norman, additional, Teerlink, John R., additional, Whellan, David J., additional, and Wittes, Janet T., additional

Published
2022
Full Text
View/download PDF

195. INCIDENCE AND PROGNOSIS OF WORSENING RENAL FUNCTION IN PATIENTS WITH HEART FAILURE AND SECONDARY MITRAL REGURGITATION: THE COAPT TRIAL

Author

Kong, Jeremy, primary, Zaroff, Jonathan G., additional, Ambrosy, Andrew P., additional, Ku, Ivy, additional, Mishell, Jacob M., additional, Kotinkaduwa, Lak, additional, Redfors, Bjorn, additional, Beohar, Nirat, additional, Ailawadi, Gorav, additional, Lindenfeld, JoAnn, additional, Abraham, William T., additional, Mack, Michael J., additional, and Stone, Gregg W., additional

Published
2022
Full Text
View/download PDF

197. Impact of baseline renal dysfunction on cardiac outcomes and end-stage renal disease in heart failure patients with mitral regurgitation: the COAPT trial

Author

Beohar, Nirat, primary, Ailawadi, Gorav, additional, Kotinkaduwa, Lak N, additional, Redfors, Björn, additional, Simonato, Matheus, additional, Zhang, Zixuan, additional, Morgan, Loren Garrison, additional, Escolar, Esteban, additional, Kar, Saibal, additional, Lim, David Scott, additional, Mishell, Jacob M, additional, Whisenant, Brian K, additional, Abraham, William T, additional, Lindenfeld, JoAnn, additional, Mack, Michael J, additional, and Stone, Gregg W, additional

Published
2022
Full Text
View/download PDF

200. Subgroup Analysis of a Randomized Controlled Trial Evaluating the Safety and Efficacy of Cardiac Contractility Modulation in Advanced Heart Failure

Author

Abraham, William T., Nademanee, Koonlawee, Volosin, Kent, Krueger, Steven, Neelagaru, Suresh, Raval, Nirav, Obel, Owen, Weiner, Stanislav, Wish, Marc, Carson, Peter, Ellenbogen, Kenneth, Bourge, Robert, Parides, Michael, Chiacchierini, Richard P., Goldsmith, Rochelle, Goldstein, Sidney, Mika, Yuval, Burkhoff, Daniel, and Kadish, Alan

Published
2011
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results